← All trials
NCT06016179
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Aug 29, 2023
- Last posted
- Nov 8, 2023
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Allegheny Health NetworkLead sponsor
- Allegheny Health NetworkReponsible party - principal investigator
- Allegheny Health NetworkSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.